<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806581</url>
  </required_header>
  <id_info>
    <org_study_id>HI-IM-001</org_study_id>
    <nct_id>NCT04806581</nct_id>
  </id_info>
  <brief_title>Clinical Study of Hepatocyte Transplantation for Liver Cirrhosis</brief_title>
  <official_title>Clinical Study of Congener Allogeneic Hepatocyte Transplantation Treatment in Patients With Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Primary Objective: To observe and determine the safety and tolerance of allogeneic&#xD;
      hepatocyte transplantation in patients with liver cirrhosis and to establish the&#xD;
      maximum-tolerated dose (MTD) and evaluate the dose-limiting toxicities (DLTs).&#xD;
&#xD;
      The Secondary Objective: To observe the therapeutic efficacy of allogeneic hepatocyte&#xD;
      transplantation for liver cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  A traditional 3 + 3 dose escalation design will be implemented.&#xD;
&#xD;
        -  Successive cohorts of participants (3 or 3+3 participants /cohort) will start on a fixed&#xD;
           cell numbers of allogeneic hepatocyte in three cohorts separately: L dose (low cell&#xD;
           numbers); M dose (medium cell numbers); H dose (high cell numbers).&#xD;
&#xD;
        -  The 1st cohort will be given dose of L.&#xD;
&#xD;
        -  The 2nd cohort will be given dose of M.&#xD;
&#xD;
        -  The 3rd cohort will be given dose of H.&#xD;
&#xD;
        -  Dose escalation will continue until the maximum-tolerated dose (MTD). If no DLTs are&#xD;
           observed for 28days after administration of the last dose, a new cohort will be enrolled&#xD;
           at the next planned dose level. If DLTs are observed in 2 of the three participants, the&#xD;
           MTD will be determined to be the dose administered to the previous cohort. If DLTs are&#xD;
           observed in one participant in the cohort, another three participants will be treated&#xD;
           with the same dose level. If the new three participants aren't observed DLTs, another&#xD;
           cohort will be enrolled at the upper dose. If at least one of the new three ones are&#xD;
           observed DLTs, the below dose will be the MTD.&#xD;
&#xD;
        -  MTD will stopped by testing increasing up to the H dose.&#xD;
&#xD;
        -  Toxicities will be graded using the Common Terminology Criteria for Adverse Events&#xD;
           Version 5.0 (CTCAE 5.0).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Sequential Assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose</measure>
    <time_frame>28days</time_frame>
    <description>Observe the safety and tolerance after single infusion of hepatocyte.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose-Limiting Toxicities</measure>
    <time_frame>28days</time_frame>
    <description>Observe the safety and tolerance after single infusion of hepatocyte.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Allogeneic Hepatocyte Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will each be administered L dose for one time. With 28days follow-up after the cells infusion.&#xD;
Allogeneic hepatocyte cell numbers: L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allogeneic Hepatocyte Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will each be administered M dose for one time. With 28days follow-up after the cells infusion.&#xD;
Allogeneic hepatocyte cell numbers: M</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allogeneic Hepatocyte Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will each be administered H dose for one time. With 28days follow-up after the cells infusion.&#xD;
Allogeneic hepatocyte cell numbers: H</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allogeneic Hepatocyte</intervention_name>
    <description>Allogeneic hepatocyte with cell numbers L,M,H respectively.</description>
    <arm_group_label>Allogeneic Hepatocyte Cohort 1</arm_group_label>
    <arm_group_label>Allogeneic Hepatocyte Cohort 2</arm_group_label>
    <arm_group_label>Allogeneic Hepatocyte Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  The age at the time of signing the informed consent from 18 to 70 years old (including&#xD;
             the boundary value), both male and female;&#xD;
&#xD;
          -  Clinical diagnosis of liver cirrhosis;&#xD;
&#xD;
          -  Be able to understand and sign informed consent.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Combined with liver cancer or other malignant tumors;&#xD;
&#xD;
          -  Patients who can't cooperate;&#xD;
&#xD;
          -  Prothrombin time (PT) exceeded the upper limit of normal control for 3-5 seconds or&#xD;
             more;&#xD;
&#xD;
          -  International normalized ratio (INR) &gt;1.5;&#xD;
&#xD;
          -  PLT&lt;60×109/L；&#xD;
&#xD;
          -  Recently use of anticoagulant or antiplatelet drugs (last 7 days);&#xD;
&#xD;
          -  Recently (last 4 weeks) had upper gastrointestinal bleeding or spontaneous celiac&#xD;
             inflammation;&#xD;
&#xD;
          -  Moderate or large amount of ascites;&#xD;
&#xD;
          -  The investigator assesses that the patient is unable or unwilling to comply with the&#xD;
             protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qiang Xia, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Liver Surgery, Renji Hospital affiliated to Shanghai Jiao Tong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qiang Xia, Doctor</last_name>
    <phone>0086-02168383134</phone>
    <email>xiaqiang@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yaoping Shi</last_name>
    <phone>0086-02168383134</phone>
    <email>shi_yaoping@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 16, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver cirrhosis; allogeneic hepatocyte; transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

